therapy
Results of recent multicenter       clinical trials support these findings and have made it abundantly clear that       long-term therapy with beta blockade inhibits clinical progression and has a       major impact on mortality and morbidity in patients with HF that is at least as       favorable, if not better, than that observed with angiotensin-converting enzyme       (ACE) inhibitors.
Results of recent multicenter       clinical trials support these findings and have made it abundantly clear that       long-term  @SUBJECT$  with beta blockade inhibits clinical progression and has a       major impact on mortality and morbidity  @PREDICAT$  patients with  @OBJECT$  that is at least as       favorable, if not better, than that observed with angiotensin-converting enzyme       (ACE) inhibitors.